atg4

NSC 185058, an inhibitor of ATG4B (a major cysteine protease), can also attenuate autophagic activity.

Atg4B-IN-2. A potent, selective Atg4B inhibitor with anticancer activity, inhibits both Atg4B and PLA2, enabling autophagy that counteracts the anticancer activity of anti-desiccation-resistant prostate cancer drugs.

Atg4B activator-1 (Compound 16a) is an allosteric, selective ATG4B activator with oral bioavailability, exhibiting a dissociation constant (Kd) of 0.2199 μM. It binds to the allosteric pocket of ATG4B, inducing conformational changes. Atg4B activator-1 stimulates autophagy (Autophagy) and inhibits the proliferation and migration of triple-negative breast cancer cells, making it useful for research related to triple-negative breast cancer.

FMK 9a is an irreversible inhibitor of ATG4B with IC50 values of 80 and 73 nM in the TR-FRET and cellular-based LRA assays.

LV-320 is a potent, uncompetitive ATG4B inhibitor with an IC50 of 24.5 μM and a Kd of 16 μM. LV-320 inhibits ATG4B enzymatic activity, blocks autophagic flux in cells, and is stable, non-toxic, and active in vivo. These findings suggest that LV-320 will serve as a relevant chemical tool to study the various roles of ATG4B in cancer and other contexts [1].

S130 is a high affinity, selectiveATG4B (a major cysteine protease) inhibitor (IC50 of 3.24 μM).It suppresses autophagy flux.